Rani Therapeutics Holdings (RANI) Current Deferred Revenue (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Current Deferred Revenue of $6.8 million for Q1 2026, little changed quarter-over-quarter from $6.8 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $6.8 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue changed N/A year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $6.8 million (changed N/A YoY), while the FY2025 annual figure was $6.8 million, changed N/A from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $6.8 million, roughly flat from $6.8 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $6.8 million in Q4 2025, with the low at $600000.0 in Q3 2024.
- The 3-year median for Current Deferred Revenue is $6.8 million (2025), against an average of $4.8 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.12 Mn |
| Mar 31, 2026 | 6.83 Mn |
| Dec 31, 2025 | 6.83 Mn |
| Sep 30, 2024 | 600,000.00 |
| Dec 31, 2020 | 2.72 Mn |